Back to News
Market Impact: 0.35
Lisata Therapeutics Acquires Marea Therapeutics; Announces Concurrent Private Placement
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
Lisata Therapeutics acquired clinical-stage biotech Marea Therapeutics in a stock-for-stock transaction. Marea develops genetically informed therapies for cardioendocrine diseases, expanding Lisata's clinical-stage pipeline; the article excerpt did not disclose transaction value, exchange terms, or expected financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
LSTA0.65
More News
- Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
- California AG Says Paramount-WBD Merger Would Hurt the State
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- Lucid et Bolt s'associent pour développer et déployer à grande échelle des solutions de mobilité autonome en Europe
- Halozyme prices $1.3 billion convertible notes offering